Featured News See All September 3, 2024 REGENXBIO Announces Positive Data from Pivotal Dose Level of RGX-121 Demonstrating Long-Term Systemic Effect August 1, 2024 REGENXBIO Reports Second Quarter 2024 Financial Results and Recent Operational Highlights August 1, 2024 REGENXBIO ANNOUNCES NEW POSITIVE DATA FROM AFFINITY DUCHENNE® TRIAL OF RGX-202 Year All202420232022202120202019201820172016201520142013201220112009 Sep 03, 2024 REGENXBIO Announces Positive Data from Pivotal Dose Level of RGX-121 Demonstrating Long-Term Systemic Effect Aug 29, 2024 REGENXBIO to Participate in Upcoming Investor Conferences Aug 27, 2024 REGENXBIO Announces Presentation at the Society for the Study of Inborn Errors of Metabolism (SSIEM) 2024 Annual Symposium Aug 08, 2024 REGENXBIO to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference Aug 01, 2024 REGENXBIO Reports Second Quarter 2024 Financial Results and Recent Operational Highlights Aug 01, 2024 REGENXBIO ANNOUNCES NEW POSITIVE DATA FROM AFFINITY DUCHENNE® TRIAL OF RGX-202 Jul 25, 2024 REGENXBIO to Host Conference Call on August 1 to Discuss Second Quarter 2024 Financial Results and Recent Operational Highlights
Sep 03, 2024 REGENXBIO Announces Positive Data from Pivotal Dose Level of RGX-121 Demonstrating Long-Term Systemic Effect
Aug 27, 2024 REGENXBIO Announces Presentation at the Society for the Study of Inborn Errors of Metabolism (SSIEM) 2024 Annual Symposium
Aug 08, 2024 REGENXBIO to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference
Aug 01, 2024 REGENXBIO Reports Second Quarter 2024 Financial Results and Recent Operational Highlights
Jul 25, 2024 REGENXBIO to Host Conference Call on August 1 to Discuss Second Quarter 2024 Financial Results and Recent Operational Highlights
